Ernexa Therapeutics Q3'26 EPS Estimate Is $(3.84)
Ernexa Therapeutics is expected to report Q3'26 results on November 11. EPS is anticipated at $(3.84); the report time is not specified.
Related stories
NHPC Q2 consolidated revenue from operations at 44.83 billion rupees
M impact | EQUITY | Nov 04, 2026, 01:59 PM UTC
MGE Energy Reports Q3 2026 Operating Revenue of $190.4 Million
M impact | EQUITY | Nov 04, 2026, 01:59 PM UTC
US Equity Futures Rise Pre-Bell as Traders Assess Midterm Election Results
US equity futures rose before the bell as traders assessed the implications of a Democratic win in the US midterm elections.
M impact | EQUITY | Nov 04, 2026, 01:59 PM UTC
NHPC Reports Q2 Consolidated Net Profit of 15.49 Billion Rupees
M impact | EQUITY | Nov 04, 2026, 01:59 PM UTC
Pliant Raises $80 Million in Series C Funding
Seaya Nova and Speedinvest led the oversubscribed round. Pliant is opening its commercial payments infrastructure to AI agents.
L impact | EQUITY | Nov 04, 2026, 01:59 PM UTC
Kyndryl Q2 Adjusted Earnings Rise as Revenue Falls; Reaffirms 2026 Outlook
Kyndryl reported higher adjusted earnings and lower revenue for Q2, and reaffirmed its 2026 revenue outlook.
M impact | EQUITY | Nov 04, 2026, 01:59 PM UTC